News
Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...
Investor's Business Daily on MSN53m
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion PharmaThree new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback